- Report
- June 2020
- 61 Pages
North America
From €1448EUR$1,500USD£1,242GBP
- Drug Pipelines
- September 2020
- 137 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- July 2020
- 152 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- June 2022
- 102 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2022
- 47 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- March 2021
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2020
- 210 Pages
Global
From €5183EUR$5,370USD£4,446GBP
- Report
- February 2024
- 199 Pages
Global
From €3475EUR$3,600USD£2,981GBP
Neutropenia Drug is a type of drug used to treat immune disorders, specifically those that involve a decrease in the number of neutrophils, a type of white blood cell. Neutropenia can be caused by a variety of conditions, including chemotherapy, radiation therapy, and certain infections. Neutropenia drugs are designed to increase the number of neutrophils in the body, helping to reduce the risk of infection and other complications. These drugs are typically administered intravenously or orally, depending on the severity of the condition.
The Neutropenia Drug market is highly competitive, with a number of companies offering products to treat this condition. Some of the major players in this market include Amgen, Novartis, Pfizer, Merck, and Roche. These companies offer a range of products, including monoclonal antibodies, cytokines, and other biologics. Additionally, there are a number of smaller companies that offer generic versions of these drugs. Show Less Read more